Q-omics provides the consensus-scored PANDAR profile across patient tissues and cancer cell-line models. PANDAR expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PANDAR is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, PANDAR RNA expression shows 4,428 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, THCA, and STAD as cancer lineages where PANDAR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PANDAR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PANDAR survival associations across molecular data types. PANDAR RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PANDAR RNA expression–survival associations across cancer types. High PANDAR expression shows unfavorable associations in BLCA, UVM, MESO, LAML, PRAD and TGCT. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PANDAR RNA expression.
This table summarizes PANDAR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PANDAR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PANDAR shows lower tumor expression in KIRC and KIRP and higher tumor expression in THCA, BRCA and CHOL. The THCA box plot shows higher PANDAR RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .015).
This table shows molecular features associated with PANDAR in patient tissues and cancer cell lines. In patient samples, PANDAR shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
